101 related articles for article (PubMed ID: 22245670)
1. Influx of extracellular calcium participates in rituximab-enhanced ionizing radiation-induced apoptosis in Raji cells.
Fengling M; Qingxiang G; Lijia Z; Wei Z
Toxicol Lett; 2012 Mar; 209(3):221-6. PubMed ID: 22245670
[TBL] [Abstract][Full Text] [Related]
2. Rituximab sensitizes a Burkitt lymphoma cell line to cell killing by X-irradiation.
Fengling M; Fenju L; Wanxin W; Lijia Z; Jiandong T; Zu W; Xin Y; Qingxiang G
Radiat Environ Biophys; 2009 Nov; 48(4):371-8. PubMed ID: 19652992
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.
Skvortsova I; Popper BA; Skvortsov S; Saurer M; Auer T; Moser R; Kamleitner H; Zwierzina H; Lukas P
J Radiat Res; 2005 Jun; 46(2):241-8. PubMed ID: 15988143
[TBL] [Abstract][Full Text] [Related]
4. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
[TBL] [Abstract][Full Text] [Related]
5. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
6. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
7. [Anti-CD20 monoclonal antibody RTX enhances radiosensitivity of lymphoma cells].
Min FL; Liu FJ; Wen WX; Zhai LJ; Zhou W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):660-5. PubMed ID: 20561423
[TBL] [Abstract][Full Text] [Related]
8. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
[TBL] [Abstract][Full Text] [Related]
9. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab.
Daniels I; Turzanski J; Haynes AP
Br J Haematol; 2008 Jul; 142(3):394-403. PubMed ID: 18544085
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression.
Song L; Zhang W; Chen H; Zhang X; Wu H; Ma M; Wang Z; Gu N; Zhang Y
Int J Nanomedicine; 2019; 14():921-936. PubMed ID: 30787607
[TBL] [Abstract][Full Text] [Related]
11. Modulating Ca2+ in radiation-induced apoptosis suppresses DNA fragmentation but does not enhance clonogenic survival.
Voehringer DW; Story MD; O'Neil RG; Meyn RE
Int J Radiat Biol; 1997 Mar; 71(3):237-43. PubMed ID: 9134012
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
13. Cellular internalization and mechanism of cytotoxicity of ¹³¹I-rituximab in Raji cells.
Kumar C; Pandey BN; Samuel G; Venkatesh M
J Environ Pathol Toxicol Oncol; 2013; 32(2):91-9. PubMed ID: 24099423
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin enhances (131)I-rituximab induced cell death in Raji cells.
Kumar C; Pandey BN; Samuel G; Venkatesh M
J Cancer Res Ther; 2015; 11(4):823-9. PubMed ID: 26881525
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and dose-response of residual 53BP1/gamma-H2AX foci: co-localization, relationship with DSB repair and clonogenic survival.
Marková E; Schultz N; Belyaev IY
Int J Radiat Biol; 2007 May; 83(5):319-29. PubMed ID: 17457757
[TBL] [Abstract][Full Text] [Related]
16. Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.
Singh V; Gupta D; Arora R; Tripathi RP; Almasan A; Macklis RM
PLoS One; 2014; 9(11):e111113. PubMed ID: 25364827
[TBL] [Abstract][Full Text] [Related]
17. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
Stel AJ; Ten Cate B; Jacobs S; Kok JW; Spierings DC; Dondorff M; Helfrich W; Kluin-Nelemans HC; de Leij LF; Withoff S; Kroesen BJ
J Immunol; 2007 Feb; 178(4):2287-95. PubMed ID: 17277134
[TBL] [Abstract][Full Text] [Related]
18. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Geng L; Cuneo KC; Fu A; Tu T; Atadja PW; Hallahan DE
Cancer Res; 2006 Dec; 66(23):11298-304. PubMed ID: 17145876
[TBL] [Abstract][Full Text] [Related]
20. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
